Financials data is unavailable for this security.
View more
Year on year SMS Pharmaceuticals Ltd grew revenues 35.86% from 5.22bn to 7.09bn while net income improved from a loss of 70.59m to a gain of 498.26m.
| Gross margin | 30.12% |
|---|---|
| Net profit margin | 7.69% |
| Operating margin | 12.42% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, SMS Pharmaceuticals Ltd increased its cash reserves by 393.16%, or 287.32m. The company earned 501.25m from its operations for a Cash Flow Margin of 7.07%. In addition the company generated 306.79m cash from financing while 520.72m was spent on investing.
| Cash flow per share | 10.54 |
|---|---|
| Price/Cash flow per share | 28.14 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 805.82%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.32% |
|---|---|
| Div growth rate (5 year) | 9.86% |
| Payout ratio (TTM) | 4.46% |
| EPS growth(5 years) | 4.47 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 279.56 |
More ▼
